Conditions: Type 1 Diabetes
Keywords: bionic pancreas artificial pancreas insulin glucagon clamp
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 20
Healthy volunteers: no

Brief summary:
This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of Glucagon for Injection (Eli Lilly).

Detailed description:
This study will test the hypothesis that micro-doses of a new formulation of stable glucagon, Xerisol Glucagon (Xeris Pharmaceuticals), will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of a freshly reconstituted formulation of glucagon that has poor stability in solution, Glucagon for Injection (Eli Lilly).

Arms:
arm 1: Xeris glucagon 50 micrograms, subcutaneous injection arm 2: Lilly glucagon 30 micrograms, subcutaneous injection

Interventions: intervention 1: Xeris glucagon intervention 2: Lilly glucagon
Intervention descriptions: intervention 1: The subject is given an injection of xeris glucagon intervention 2: The subject is given an injection of lilly glucagon

Protocol document:
Prot_SAP_000.pdf: